Sign In
Buy ARQT
$21.35
+0.560 (+2.69%)
At Close: Jun 03, 2026
Arcutis Completes Enrollment in Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema
09:00am, Monday, 26'th Oct 2020
WESTLAKE VILLAGE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediat
Orbimed Capital increased stake in Arcutis Biotherapeutics, Inc.
12:00am, Tuesday, 06'th Oct 2020
Orbimed Capital increased stake in Arcutis Biotherapeutics, Inc.
Why Arcutis Biotherapeutics Stock Is Plunging Today | The Motley Fool
04:40pm, Friday, 02'nd Oct 2020
The company announced the pricing of a public offering of common stock.
Mid-Morning Market Update: Markets Open Lower; US Unemployment Rate Falls To 7.9% In September
12:00am, Friday, 02'nd Oct 2020
Following the market opening Friday, the Dow traded down 0.73% to 27613.64 while the NASDAQ fell 0.92% to 11222.86. The S&P also fell, dropping 0.70% to 3,357.14.
The U.S....
The Daily Biotech Pulse: Eton Snags Second FDA Nod For Month, Vaccine Updates from Moderna, CureVac
12:00am, Wednesday, 30'th Sep 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 29)
Acceleron Pharma Inc (...
Arcutis Announces Second Quarter 2020 Financial Results and Provides Business Update
08:02pm, Tuesday, 11'th Aug 2020
* Robust pipeline anticipated to deliver two Phase 3 and four Phase 2 data events in 2020 and 2021 * Arcutis currently expects no impact to its previously disclosed clinical timelines due to COVID-
Arcutis to Present at the Wedbush PacGrow Healthcare Conference
01:00pm, Monday, 10'th Aug 2020
WESTLAKE VILLAGE, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo
Bethany Dudek Joins Arcutis as Vice President of Quality
01:00pm, Tuesday, 04'th Aug 2020
WESTLAKE VILLAGE, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo
Immunic Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:IMUX)
10:33am, Tuesday, 04'th Aug 2020
Immunic announced positive top line data for IMU-838. Catalyst Pharma gets stung in FDA lawsuit.
* Data demonstrate potential “Best in Class” topical PDE4 inhibitor roflumilast significantly improves signs and symptoms of chronic plaque psoriasis * Phase 3 topline data anticipated first ha
* Once-daily roflumilast demonstrated favorable safety and tolerability over 52 to 64 weeks of treatment * At 52 to 64 weeks of treatment, 44% of subjects had attained an IGA of clear or almost cle
Arcutis Appoints Patrick Burnett, M.D., Ph.D., FAAD, as Chief Medical Officer
01:00pm, Monday, 27'th Jul 2020
* Experienced industry leader to head Arcutis’ clinical development programs * Appointment aligns with Arcutis’ strategy of building a team with deep dermatology expertise * Howard Welgus, M.D
U.S. IPO Week Ahead: Tax Software Leads A Diverse 7-IPO Week
08:52am, Saturday, 25'th Jul 2020
Seven IPOs and one SPAC plan to raise $2.1 billion in the week ahead, led by tax software provider Vertex.
Stocks To Watch: Big Focus On Big Tech
08:26am, Saturday, 25'th Jul 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Roflumilast foam potential “Best in Class” topical PDE4 inhibitor in foam formulationScalp psoriasis affects more than 2.5 million U.S. patientsPhase 2b topline data anticipated.
